CDT Equity Seeks Shareholder Nod for Massive Dilution: 12M+ Warrant Shares and Reverse Split to Stay Listed

summarizeSummary

CDT Equity's preliminary proxy asks shareholders to greenlight extreme dilution — up to 12.1 million shares from pre-funded warrants — and a reverse split to maintain its Nasdaq listing, alongside auditor ratification and approval of a convertible note issuance.

check_boxKey Events · Corporate Governance and Compliance · CDT

• 12.1M Share Warrant Approval Sought

  Proposal 5 asks shareholders to approve issuance of up to 12,131,770 shares upon exercise of pre-funded warrants issued to Sarborg investors as consideration for a 4.76% stake in Sarborg. This represents potential dilution of over 1,500% relative to the ~786,716 shares currently outstanding.

• Reverse Split Authorization Up to 1-for-500

  Proposal 3 grants the board discretion to implement one or more reverse stock splits at ratios between 1-for-2 and 1-for-100, with an aggregate cap of 1-for-500, to maintain Nasdaq's $1 minimum bid price. The company recently completed a 1-for-10 reverse split on July 17, 2026.

• Convertible Note and Warrant Issuance to J.J. Astor

  Proposal 4 seeks approval for shares issuable upon conversion of a $1.97M senior secured convertible note and exercise of 91,250 warrants at $7.20 per share. The note carries a variable conversion price at a discount to market, with default provisions that increase the outstanding amount to 120%.

• Auditor Ratification After Two Changes in a Year

  Proposal 2 asks shareholders to ratify Carr, Riggs & Ingram, L.L.C. as the independent auditor for fiscal 2026, following the dismissal of CBIZ CPAs in June 2026 and the resignation of Marcum LLP in April 2025. Material weaknesses in internal controls were cited by both prior auditors.

auto_awesomeAnalysis · CDT · Life Sciences

CDT Equity is asking shareholders to approve the issuance of up to 12.1 million shares from pre-funded warrants tied to its Sarborg stake acquisition — a move that would massively dilute existing holders given the company's current ~787,000 shares outstanding. Simultaneously, the board wants authority to execute one or more reverse stock splits at ratios up to 1-for-500 to keep the stock above Nasdaq's $1 minimum bid. The proxy also seeks ratification of a new auditor after two changes in a year, and approval for shares underlying a toxic convertible note with J.J. Astor & Co. that carries a variable conversion price. With only $97,000 in cash and a going concern warning, these proposals are a survival package — but one that could crush current shareholders if the warrants are exercised.